{{medical}}
{{drugbox
| Verifiedfields = changed
| verifiedrevid = 443376027
| IUPAC_name = 1H-pyrazolo[3,4-d]pyrimidin-4(2H)-one
| image = Allopurinol V.1.svg
| width = 150
| image2 = Allopurinol_3d_structure.png

<!--Clinical data-->
| tradename = Lopurin, Zyloprim
| Drugs.com = {{drugs.com|monograph|allopurinol}}
| MedlinePlus = a682673
| pregnancy_category = C(USA)
| legal_US = Rx-only
| routes_of_administration = tablet (100, 300 mg)

<!--Pharmacokinetic data-->
| bioavailability = 78±20%
| protein_bound = Negligible
| metabolism = hepatic (80% oxypurinol, 10% allopurinol ribosides)
| elimination_half-life = 2 hours (oxypurinol 18-30 hours)

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 315-30-0
| ATC_prefix = M04
| ATC_suffix = AA01
| ATC_supplemental = 
| PubChem = 2094
| DrugBank_Ref = {{drugbankcite|changed|drugbank}}
| DrugBank = DB00437
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 2010
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 63CZ7GJN5I
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00224
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 40279
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1467

<!--Chemical data-->
| C=5 | H=4 | N=4 | O=1 
| molecular_weight = 136.112 g/mol
| smiles = c1c2c([nH]n1)ncnc2O
| InChI = 1/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = OFCNXPDARWKPPY-UHFFFAOYSA-N
}}

'''别嘌呤醇'''（{{lang-en|'''Allopurinol'''}}，又名'''别嘌醇'''、'''異嘌呤醇'''）是主治[[高尿酸血症|高尿酸血症]]（[[血浆|血浆]]中的[[尿酸|尿酸]]浓度过高）及其并发症[[痛風病|痛風病]]等的药物<ref name="pmid16507884">{{cite journal |pages=87–114 |pmc=2233605 |doi=10.1124/pr.58.1.6 |title=Therapeutic Effects of Xanthine Oxidase Inhibitors: Renaissance Half a Century after the Discovery of Allopurinol |year=2006 |last1=Pacher |first1=P. |journal=Pharmacological Reviews |volume=58 |pmid=16507884 |last2=Nivorozhkin |first2=A |last3=Szabó |first3=C |issue=1}}</ref>。

== 作用机理 ==
别嘌呤醇是一种嘌呤类似物；它是[[次黄嘌呤|次黄嘌呤]]（体内一种常见的[[嘌呤|嘌呤]]）的异构体且是[[黄嘌呤氧化酶|黄嘌呤氧化酶]]的[[酶抑制剂|酶抑制剂]]<ref name="pmid16507884"/>。黄嘌呤氧化酶负责将次黄嘌呤和[[黄嘌呤|黄嘌呤]]的连续氧化，最终产生的产物是[[尿酸|尿酸]]，这是人类的嘌呤代谢终产物<ref name="pmid16507884"/>。除了阻断尿酸的生成之外，抑制黄嘌呤氧化酶会使得次黄嘌呤以及黄嘌呤的量增加，这两者会转变为与之密切相关的嘌呤[[核苷酸|核苷酸]]——[[腺苷酸|腺苷酸]]以及[[鸟苷酸|鸟苷酸]]。这两种核苷酸含量水平的增高会反馈性抑制[[酰胺磷酸核糖基转移酶|酰胺磷酸核糖基转移酶]]，此酶催化嘌呤生物合成的首个且为限速步骤。因此，别嘌呤醇既减少了尿酸的生成又阻止了嘌呤的合成。
== 急性過敏 ==
一些人會有嚴重的過敏，產生「[[史蒂文生氏-強生症候群|史蒂文生氏-強生症候群]]」或「[[毒性表皮壞死溶解症|毒性表皮壞死溶解症]]」，死亡率高；基因檢測可以過濾出會發生嚴重過敏的病人。

==参考文献==
{{Reflist}}

==外部連接==
* [http://www.drugs.com/cdi/zyloprim.html Zyloprim] (patient information)
* [http://www.pharmgkb.org/pathway/PA165980774 Allopurinol pathway on PharmGKB]

{{tsl|en|Template:Antigout preparations}}<br>
{{Adenosinergics}}

[[分类:抗痛风剂|分类:抗痛风剂]]
[[分类:黄嘌呤氧化酶抑制剂|分类:黄嘌呤氧化酶抑制剂]]
[[分类:世界卫生组织基本药物|分类:世界卫生组织基本药物]]